411 related articles for article (PubMed ID: 30396996)
1. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
2. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
3. [Conditional medium of gastric cancer mesenchymal stem cells promotes PD-L1 expression in gastric cancer cells and tumor growth via upregulating VGLL4].
Ding Y; Zhu W; Wang Q; Chen B; Wang M; Zhao Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):321-327. PubMed ID: 35583061
[TBL] [Abstract][Full Text] [Related]
4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
5. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
[TBL] [Abstract][Full Text] [Related]
7. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
[TBL] [Abstract][Full Text] [Related]
8. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
9. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
10. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
Lu M; Wang K; Ji W; Yu Y; Li Z; Xia W; Lu S
Cell Immunol; 2022 Sep; 379():104577. PubMed ID: 35870429
[TBL] [Abstract][Full Text] [Related]
13. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
Dorand RD; Nthale J; Myers JT; Barkauskas DS; Avril S; Chirieleison SM; Pareek TK; Abbott DW; Stearns DS; Letterio JJ; Huang AY; Petrosiute A
Science; 2016 Jul; 353(6297):399-403. PubMed ID: 27463676
[TBL] [Abstract][Full Text] [Related]
14. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
15. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
16. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H
Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094
[TBL] [Abstract][Full Text] [Related]
17. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
Jiao S; Li C; Hao Q; Miao H; Zhang L; Li L; Zhou Z
Nat Commun; 2017 Jan; 8():14058. PubMed ID: 28051067
[TBL] [Abstract][Full Text] [Related]
18. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
[TBL] [Abstract][Full Text] [Related]
19. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
Zeng Y; Stauffer S; Zhou J; Chen X; Chen Y; Dong J
J Biol Chem; 2017 Sep; 292(36):15028-15038. PubMed ID: 28739871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]